E-cigarette effectiveness in smoking cessation

Nov.21.2022
E-cigarette effectiveness in smoking cessation
A study by the UK Cochrane Group found that nicotine e-cigarettes can improve smoking cessation rates.

Recently, the UK-based Cochrane Collaboration conducted 78 studies involving 22,052 smokers, comparing the use of electronic cigarettes with the following factors:


Nicotine replacement therapy (such as patches or gum);


Varenicline, a medication that helps people quit smoking;


Nicotine-free electronic cigarette;


Other types of electronic cigarettes that contain nicotine (such as pods);


Actions of support, such as advice or consultation.


The research was mostly conducted in the United States (34 studies), United Kingdom (16 studies), and Italy (8 studies).


Key Conclusion


Using nicotine-containing e-cigarettes is more effective than using nicotine replacement therapy or non-nicotine e-cigarettes for quitting smoking. The most common adverse effects of using e-cigarettes with nicotine are throat or oral irritation, headaches, coughing and nausea. As people continue to use nicotine e-cigarettes, these effects become lessened over time.


Research summary


There is strong evidence to suggest that nicotine-containing e-cigarettes are more effective for smoking cessation than NRT, while moderate quality evidence suggests that nicotine-containing e-cigarettes are more effective for smoking cessation than non-nicotine e-cigarettes. Comparing nicotine replacement therapy to standard care or no treatment also shows benefit, but with lower certainty and requiring further research to confirm the effect. In most cases, the confidence intervals for data on AEs, SAEs, and other safety indicators are broad, with no differences observed between nicotine and non-nicotine e-cigarettes in terms of AEs, or between nicotine e-cigarettes and NRT. The overall incidence rate of SAEs was low across all study groups. No evidence was found for serious harm from nicotine e-cigarettes, but the longest follow-up period was two years and the number of studies was limited. The primary limitation of the evidence base continues to be imprecision due to limited numbers of RCTs and typically low event rates, but further RCTs are currently ongoing. To ensure that this review continues to provide up-to-date information for decision-makers, it is a living system review. Searches are conducted monthly and the review is updated when new relevant evidence becomes available. Please refer to the Cochrane Systematic Reviews Database for the current status of this review.


Statement:


This article is based on third-party information that has been edited by machine translation, and is only intended for industry communication and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness or accuracy of the article's content. The translation of this article is only for the purpose of industry-related communication and research.


Due to limitations in the translator's abilities, the translated article may not fully express the original content. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government in regards to any domestic, Hong Kong, Macau, Taiwan, or international statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to have it removed.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

South Korea Busts Etomidate-Laced E-Cigarette Smuggling Ring; Devices Suspected to Serve as Drug Carriers for 2 Million Users
South Korea Busts Etomidate-Laced E-Cigarette Smuggling Ring; Devices Suspected to Serve as Drug Carriers for 2 Million Users
Malaysian authorities and South Korea’s intelligence agency busted an international syndicate smuggling e-cigarettes laced with etomidate and cocaine. The group, led by a 31-year-old Singaporean, planned to traffic 20,000 devices monthly via transit hubs like Malaysia. Large drug hauls and packaging materials were seized, with South Korean intelligence providing key information after monitoring the group since 2023.
Jul.09 by 2FIRSTS.ai
Global e-cigarette expo in Dubai showcases new products and trends.
Global e-cigarette expo in Dubai showcases new products and trends.
World Vape Show Dubai 2025, held from June 18-20, showcased innovative e-cigarette products at Dubai World Trade Center.
Jun.20 by 2FIRSTS.ai
2Firsts Exclusive Interview | JTI Launches New-Generation Ploom AURA, Focuses on Enhanced Flavor and Customization
2Firsts Exclusive Interview | JTI Launches New-Generation Ploom AURA, Focuses on Enhanced Flavor and Customization
2Firsts interviewed Nick Geens, JTI’s Vice President of Reduced-Risk Products, to discuss the new-generation heated tobacco product Ploom AURA, launched in Japan in May 2025, highlighting enhanced flavor, customizable heating modes, harm reduction concept, and future market plans.
Jul.16
Exclusive Interview with Malaysian Brand ASDF: "Cartridge" Design Banned Domestically, Shifts Focus to Markets Like South Korea
Exclusive Interview with Malaysian Brand ASDF: "Cartridge" Design Banned Domestically, Shifts Focus to Markets Like South Korea
ASDF, a top Malaysian brand known for its “retro cassette” design, is facing regulatory challenges at home while expanding abroad. At the World Vape Show Dubai, 2Firsts interviewed Business Development Director Kinson Tan to discuss the brand’s response to market changes and its strategic shift toward regions like South Korea.
Jun.25 by 2FIRSTS.ai
BAT CEO Posts on Social Media: glo Hilo Is the Company's Most Groundbreaking Heated Tobacco Product to Date
BAT CEO Posts on Social Media: glo Hilo Is the Company's Most Groundbreaking Heated Tobacco Product to Date
BAT CEO Tadeu Marroco posted on social media, calling glo Hilo the company’s most groundbreaking heated tobacco product to date. He stated that it marks a significant step forward in BAT’s accelerated push toward achieving a smoke-free future by 2035.
Jun.26 by 2FIRSTS.ai
PMI Launches IQOS ILUMA i Series in Saudi Arabia to Support a Smoke-Free Future
PMI Launches IQOS ILUMA i Series in Saudi Arabia to Support a Smoke-Free Future
Philip Morris International (PMI) has launched its next-generation heated tobacco products, the IQOS ILUMA i series, in Saudi Arabia, debuting with two devices: ILUMA i PRIME and ILUMA i.
Jul.09 by 2FIRSTS.ai